JP5341526B2 - 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療 - Google Patents

免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療 Download PDF

Info

Publication number
JP5341526B2
JP5341526B2 JP2008557846A JP2008557846A JP5341526B2 JP 5341526 B2 JP5341526 B2 JP 5341526B2 JP 2008557846 A JP2008557846 A JP 2008557846A JP 2008557846 A JP2008557846 A JP 2008557846A JP 5341526 B2 JP5341526 B2 JP 5341526B2
Authority
JP
Japan
Prior art keywords
mdash
configuration
mice
cooh
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008557846A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529523A (ja
JP2009529523A5 (https=
Inventor
バウアー，ジャック
シャバロリ，カルロ
ムテル，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OM Pharma SA
Original Assignee
OM Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OM Pharma SA filed Critical OM Pharma SA
Publication of JP2009529523A publication Critical patent/JP2009529523A/ja
Publication of JP2009529523A5 publication Critical patent/JP2009529523A5/ja
Application granted granted Critical
Publication of JP5341526B2 publication Critical patent/JP5341526B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008557846A 2006-03-09 2007-03-09 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療 Expired - Fee Related JP5341526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2006/050748 2006-03-09
IBPCT/IB2006/050748 2006-03-09
PCT/IB2007/000567 WO2007102081A2 (en) 2006-03-09 2007-03-09 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines

Publications (3)

Publication Number Publication Date
JP2009529523A JP2009529523A (ja) 2009-08-20
JP2009529523A5 JP2009529523A5 (https=) 2010-02-18
JP5341526B2 true JP5341526B2 (ja) 2013-11-13

Family

ID=38475231

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008557846A Expired - Fee Related JP5341526B2 (ja) 2006-03-09 2007-03-09 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療

Country Status (14)

Country Link
US (3) US7915240B2 (https=)
EP (1) EP2051728A4 (https=)
JP (1) JP5341526B2 (https=)
KR (1) KR20080105048A (https=)
CN (1) CN101511379A (https=)
AU (1) AU2007222135B2 (https=)
BR (1) BRPI0708363A2 (https=)
CA (1) CA2645053A1 (https=)
IL (1) IL192837A (https=)
MX (1) MX2008011360A (https=)
NO (1) NO20084195L (https=)
RU (1) RU2498813C2 (https=)
WO (1) WO2007102081A2 (https=)
ZA (1) ZA200806266B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007102081A2 (en) 2006-03-09 2007-09-13 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
KR101108161B1 (ko) 2009-12-24 2012-01-31 삼성모바일디스플레이주식회사 유기 발광 표시 장치 및 그 제조방법
US10065978B2 (en) * 2015-11-24 2018-09-04 University Of South Carolina Cysteine-modifying substrate analogue inhibitors of ribose 5-phosphate isomerase for parasitic diseases, along with methods of their formation and use
US10682359B2 (en) 2017-03-31 2020-06-16 University Of South Carolina Inhibitors of glucose kinases, along with methods of their formation and use
US11059842B2 (en) 2019-04-29 2021-07-13 University Of South Carolina Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases
US11555047B2 (en) 2019-10-31 2023-01-17 University Of South Carolina One-step synthesis of phosphate-based inhibitors and applications thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL187439B1 (pl) * 1996-01-23 2004-07-30 Icn Pharmaceuticals Zastosowanie rybawiryny
JP4305662B2 (ja) * 1996-09-30 2009-07-29 大塚製薬株式会社 サイトカイン産生抑制剤及び接着抑制剤
ATE238328T1 (de) * 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
KR20010021789A (ko) 1997-08-04 2001-03-15 야스이 쇼사꾸 촉매 및 방향족 카보네이트의 제조방법
IT1296985B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO1999061412A1 (en) * 1998-05-22 1999-12-02 Welfide Corporation Hydroxamic acid derivatives and medicinal utilization thereof
CN1168702C (zh) * 1998-06-30 2004-09-29 Om药业 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
EP1261736A4 (en) * 2000-01-25 2004-12-29 Nuvelo Inc PROCESS, POLYPEPTIDES AND POLYNUCLEOTIDES, ASSOCIATED WITH "PREADIPOCYTE FACTOR-1" (PREF-1)
JP2001316260A (ja) * 2000-02-29 2001-11-13 Meiji Milk Prod Co Ltd カバラクトン類を有効成分とするＴＮＦ−α産生抑制剤
DE20220947U1 (de) * 2001-02-28 2004-09-30 Ribapharm, Inc., Costa Mesa Pyrrolo2,3-dpyrimidin-Nucleosidanaloga
RU2190422C1 (ru) * 2001-04-25 2002-10-10 Кожемякин Леонид Андреевич Аэрозоль для ингаляций фармацевтической композиции глутовент и способ лечения с его использованием
JP4902913B2 (ja) * 2001-07-11 2012-03-21 森下仁丹株式会社 ＴＮＦ−α産生抑制剤
JP2004107220A (ja) * 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
JP2004256403A (ja) * 2003-02-25 2004-09-16 Kyowa Hakko Kogyo Co Ltd ＴＮＦ−α産生抑制剤
BRPI0407519A (pt) * 2003-03-07 2006-02-14 Kowa Co derivados de benzofurano
WO2007102081A2 (en) 2006-03-09 2007-09-13 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines

Also Published As

Publication number Publication date
NO20084195L (no) 2008-10-07
WO2007102081A3 (en) 2009-04-23
US20090054378A1 (en) 2009-02-26
WO2007102081A2 (en) 2007-09-13
JP2009529523A (ja) 2009-08-20
ZA200806266B (en) 2010-05-26
KR20080105048A (ko) 2008-12-03
RU2008139985A (ru) 2010-04-20
AU2007222135A1 (en) 2007-09-13
US8618080B2 (en) 2013-12-31
EP2051728A4 (en) 2010-03-31
MX2008011360A (es) 2009-03-03
US20120178721A1 (en) 2012-07-12
CA2645053A1 (en) 2007-09-13
EP2051728A2 (en) 2009-04-29
CN101511379A (zh) 2009-08-19
AU2007222135B2 (en) 2012-02-02
RU2498813C2 (ru) 2013-11-20
IL192837A (en) 2013-12-31
US20140086960A1 (en) 2014-03-27
US7915240B2 (en) 2011-03-29
BRPI0708363A2 (pt) 2011-05-24

Similar Documents

Publication Publication Date Title
JP5341526B2 (ja) 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療
JP7189906B2 (ja) 二糖合成脂質化合物およびその使用
JP2020019810A (ja) Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
EP1091928A1 (fr) Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
WO2020051322A1 (en) Methods of treating cytokine release syndrome
CA2911914A1 (en) Stat6 inhibitors
TW202329920A (zh) 天冬氨酸的衍生物及其在肝纖維化、非酒精性肝炎等代謝等疾病的治療的應用
JP7395198B2 (ja) インターロイキン１βに関連する病態の治療のためのピリジン－スルホンアミド化合物
CA2750607C (en) Composition comprising carbohydrate esters of mycolic acid derivatives_and process for the preparation thereof
HK1132660A (en) Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
AU2012202597A1 (en) Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
US12577235B2 (en) Crystalline form of CXCR2 antagonist and application thereof
EP4458413A2 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
US12115161B2 (en) Prophylactic and/or therapeutic agent for inflammatory diseases which contains pyrrolopyrimidine compound as active ingredient
RU2803242C2 (ru) Соединения пиридинсульфонамида для лечения состояний, связанных с интерлейкином 1 бета
WO2024029528A1 (ja) アレルギー性疾患の改善用医薬組成物
US6495678B1 (en) Immunosuppressant containing glucopyranose derivative as active ingredient
JP6936496B2 (ja) 移植片対宿主病の治療剤又は予防剤、ファイブロサイト浸潤抑制剤、及び涙液減少と杯細胞の減少の抑制剤
WO2024130693A1 (zh) 精胺衍生物及其在疾病中的治疗用途
JP2024078449A (ja) 眼圧下降剤、及び緑内障若しくは高眼圧症の治療剤又は予防剤
Saggar Effect of phosphorylcholine-based small molecule analogues of the immunomodulatory nematode product ES-62 on mast cell function
WO2007142754A2 (en) Methods and compositions for cognitive alteration
US20170349618A1 (en) Disaccharide synthetic lipid compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130808

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees